



eCQM Data Element Repository

May 2025

Objectives

- Learn how the Electronic Clinical Quality Measure (eCQM) Data Element Repository helps with eCQM data mapping activities.
- Learn how a health care organization uses the Data Element Repository to understand eCQM requirements.
- Describe resources available to learn more about CMS programs that use eCQMs.

eCQM Strategy Project Background

eCQM Strategy Project Background

eCQM Strategy Project Goals

- Reduce Burden
- Increase Value
- Increase Stakeholder Involvement


Problem Statement

- Providers participating in CMS quality and value-based purchasing programs have shared challenges they experience related to the **complexity and high burden of eCQM implementation, data capture, and reporting.**

Project Scope

- **Measure Development** process from concept to the Measures Under Consideration (MUC) list
- **Electronic Clinical Quality Reporting** requirements and processes from eCQM implementation to submission
- **Tools for Development and Reporting**

eCQM Strategy Recommendations



Measure Collaboration Workspace

Measure Collaboration (MC) Workspace

- Hosted on the eCQI Resource Center (<https://ecqi.healthit.gov/mc-workspace-2>)
- Contains a set of interconnected resources, tools, and processes for eCQMs
- Promotes transparency and better interaction across stakeholder communities interested in developing and implementing more harmonized, accurate, and meaningful eCQMs
- Provides access to the eCQM Data Element Repository, an online, searchable tool that provides all the data elements associated with eCQMs used in CMS Quality Reporting Programs

How to Access the MC Workspace

ELIGIBLE CLINICIAN

- EC eCQMs

HOSPITAL

- Inpatient eCQMs
- Outpatient eCQMs

NEW TO ECQMS?

- Get Started with eCQMs
- eCQM Lifecycle
- MEASURE COLLABORATION**

 - Measure Collaboration (MC) Workspace
 - eCQM Data Element Repository (DERep)

Featured News & Events

- Apr 16, 2025
[Submit a Nomination to Join a PQM Committee...](#)
- May 15, 2025 @ 2:00pm EDT
[MADiE User Group](#)

[View All](#)

ECQM PERIOD eCQM Title or CMSID

- Any - - Any - May use partial Title or ID [Find an eCQM](#)

Overview of the MC Workspace



eCQM Data Element Repository

eCQM Data Element Repository

Example Search

<https://ecqi.healthit.gov/mc-workspace-2/data-element-repository>

- Navigate to the eCQM Data Element Repository landing page and available filters
- Filter for 2024 EH/CAH eCQMs*
- Select CMS71v13 and highlight information available on measure pages with expand and collapse features to display data elements
- Identify value sets and direct reference codes in VSAC
- Identify eCQI Resource Center measure pages
- From Data Element Repository landing page, demonstrate information available on QDM filters

*EH/CAH = Eligible Hospital/Critical Access Hospital

Anticoagulation Therapy for Atrial Fibrillation/Flutter (STK-3)

CMS Measure ID: CMS71v13

2024 » Anticoagulation Therapy for Atrial Fibrillation/Flutter

DERep Home Page

Anticoagulation Therapy for Atrial Fibrillation/Flutter (STK-3)

CMS Measure ID: CMS71v13

Performance/Reporting Period: 2024

NQF Number: Not Applicable

Description:

Ischemic stroke patients with atrial fibrillation/flutter who are prescribed or continuing to take anticoagulation therapy at hospital discharge

Data Elements and coded QDM Attributes contained within the eCQM

+ Expand all

["Assessment, Performed": "History of Atrial Ablation"] ^

["Diagnoses": "Atrial Fibrillation Or Flutter"] ^

["Diagnoses": "Hemorrhagic Stroke"] ^

["Diagnoses": "Ischemic Stroke"] (2.16.840.1.113883.3.117.1.7.1.247) ^

<https://ecqi.healthit.gov/measure-data-elements/179371>

Anticoagulation Therapy for Atrial Fibrillation/Flutter (STK-3)

CMS Measure ID: CMS71v13 (Cont'd)

["Assessment, Performed": "History of Atrial Ablation"]

View Edit Revisions Clone

eCQM Data Element

Performance/Reporting Period: 2024


Value Set Description from VSAC

CLINICAL FOCUS: The purpose of this value set is to represent concepts for a situation of a personal history of an atrial ablation.

DATA ELEMENT SCOPE: This value set may use a model element related to a diagnosis or assessment.

INCLUSION CRITERIA: Includes concepts that identify a situation for a personal history of an atrial ablation.

EXCLUSION CRITERIA: No Exclusions.

Constrained to codes in the History of Atrial Ablation value set [\(2.16.840.1.113762.1.4.1110.76\)](#) 

QDM Datatype and Definition

"Assessment, Performed"

Data elements that meet criteria using this datatype should document completion of the assessment indicated by the QDM category and its corresponding value set.

Timing:

- *relevant dateTime* references timing for an assessment that occurs at a single point in time.
- *relevant Period* references a start and stop time for an assessment that occurs over a time interval
- *author dateTime* references the time the action was recorded.
- Refer to the eCQM expression to determine allowable timings to meet measure criterion.

May 2025

<https://ecqi.healthit.gov/mcw/2024/ecqm-dataelement/assessmentperformedhistoryofatrialablation.html>¹³

Andrew Hamilton, MS, BSN, RN MS Chief Informatics Officer,
AllianceChicago

Eduardo Segovia, BS, Manager, Data Warehouse Business Analyst,
AllianceChicago

Tina Aggarwal, MS, BSN, RN, Clinical Informaticist, AllianceChicago

Health System Experience Using the eCQM Data Element Repository

Data Element Repository

Implementer Experience

Andrew Hamilton, RN, BSN, MS *Chief Informatics Officer*

Eduardo Segovia, BS *Manager, Data Warehouse Business Analyst*

Tina Aggarwal, MS, BSN, RN *Clinical Informaticist*




AllianceChicago – Who We Are

Our Mission

To improve personal, community and public health through innovative collaboration.

AllianceChicago's efforts are focused in three core areas:



User Community
60 community health centers
from 18 states






AllianceChicago now has initiatives that span 18 States and engage more than:

- 60 Safety-net Health Centers
- >3,200,000 patients
- >20 Funders
- >20 Research Affiliations




AllianceChicago Data Warehouse Overview



Prior Experience

- Universal HIV Screening Measure (CDC)
- Hepatitis C Screening (CDC)
- Contraceptive Measure (OPA)
- Heart Failure Measure Stratified by Race (NMQF)

Overview of Measure Implementation



CMS347v3: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

Our process of building the eCQM for Statin Therapy.

How we implement the measure within organizations and measure testing.

Measure Description

- Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:
- *Adults aged ≥ 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR
- *Adults aged ≥ 21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; OR
- *Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL

Performance Measures:

Measure Name	Measure Definition
Statin Therapy– ASCVD Risk Group	% of ASCVD patients age 21+ years who were prescribed or were on statin therapy during the measurement period
Statin Therapy – LDL-C level ≥ 190 mg/dL Risk Group	% of patients age 21+ years with LDL ≥ 190 mg/dL who were prescribed or were on statin therapy during the measurement period
Statin Therapy – diabetes and LDL-C level 70-189 mg/dL Risk Group	% of patients age 40-75 years with diabetes and LDL-C level 70-189 mg/dL who were prescribed or were on statin therapy during the measurement period
Statin Therapy Cohort - Follow-up Visit	Number of patients at identified as high risk of cardiovascular events (all risk groups combined) who were NOT on statin therapy at baseline who return for 1 or more follow-up visits
Statin Therapy Cohort - Newly Prescribed Statin Therapy	Number of patients at identified as high risk of cardiovascular events (all risk groups combined) who were NOT prescribed or were on statin therapy at baseline who return for 1 or more follow-up visits AND who receive a subsequent prescription for statin therapy

Measure Specification

Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

CMS Measure ID:

[CMS347v3](#)

Version:

3

NQF Number:

0

Performance/Reporting Period

2020

Description:

Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:

*Adults aged \geq 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR

*Adults aged \geq 21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level \geq 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; OR

*Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL

Data Elements contained within the eCQM

+ Expand all

[Adverse Event: Statin Allergen](#)



[Allergy, Intolerance: Statin Allergen](#)



[Diagnosis: Atherosclerosis and Peripheral Arterial Disease](#)



[Diagnosis: Breastfeeding](#)



[Diagnosis: Cerebrovascular disease, Stroke, TIA](#)



Feasibility

- Feasibility scorecard (ex: HCV)

Measure Title: HCV Learning Collaborative Feasibility Scorecard

ID	Value Set	Data Element Attributes	Value Set Code Type	Timeline	DATA AVAILABILITY		DATA ACCURACY		DATA STANDARDS		WORKFLOW	
					Is the data readily available in a structured format?	Score	Additional Characteristics	Is the information contained in the data element correct? Are the data source and recorder specified?	Score	Additional Characteristics	Are the data elements coded using a national accepted terminology standard?	Score
1	1945-1965 Birth Cohort	Administrative Code	Administrative code	Current Future								
2	UDS Visit	Administrative Code	ID10CM, ID9CM, SNOMEDCT, CDT, CPT, HCPCS, RXNORM	Current Future								
3	HCV risk factor - Current or past injection drug use	BD	TBD	Current Future								
4	HCV risk factor - History of IDU	BD	TBD	Current Future								
5	HCV risk factor - History of incarceration	BD	TBD	Current Future								
6	HCV Antibody	16.840.1.113762.1.4.1056.72	CPT Code?	Current Future								
7	Tested for HCV RNA	16.840.1.113762.1.4.1056.73	CPT Code, LOINC	Current Future								
8	HCV Diagnosis	see my email attachment	ICD	Current Future								
9	Linkage to HCV Care	BD	No available value set - will need to determine during project period - I found a ref for	Current Future								
10	HCV Treatment Initiation	Proposed med list	RxNorm Codes?	Current Future								
...	HCV Cure	16.840.1.113762.1.4.1056.73	LOINC	Current								

Assess Chart Workflow



Value Set Authority Center (VSAC)

Welcome Search Value Sets Download Browse Code Systems Help

Search the NLM Value Set Repository. Program: All Expansion Version: Latest

COVID-19 Value Sets: 0

Refine by: Steward Code System

Query: Enter value set id, codes, words... Search Clear

Search Results Value Set Details API Resource

Value Set Information Expansion Versions: eCQM Update 2019-05-10

Metadata Description Measure Grouping Members

Name: Cerebrovascular disease, Stroke, TIA
 Code System: ICD10CM, ICD9CM, SNOMEDCT
 Value Set Definition
 Definition Type: Grouping
 Definition Version: 20170504
 Program: CMS, eCQM Update 2019-05-10 using this value set
 Expansion Profile
 eCQM Update 2019-05-10 View

OID: 2.16.840.1.113762.1.4.1047.44
 Steward: Quality Insights of Pennsylvania
 Contact

Value Set Authority Center
 U.S. National Library of Medicine

Code	Description	Code System	Code System Version	Code System OID	TTY
200:69.243	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting	ICD10CM	2019	2.16.840.1.113883.6.90	PT
201:69.244	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting	ICD10CM	2019	2.16.840.1.113883.6.90	PT
222:69.249	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting	ICD10CM	2019	2.16.840.1.113883.6.90	PT
223:69.251	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage	ICD10CM	2019	2.16.840.1.113883.6.90	PT
224:69.252	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage	ICD10CM	2019	2.16.840.1.113883.6.90	PT
225:69.253	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage	ICD10CM	2019	2.16.840.1.113883.6.90	PT
226:69.254	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage	ICD10CM	2019	2.16.840.1.113883.6.90	PT
227:69.259	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage	ICD10CM	2019	2.16.840.1.113883.6.90	PT
228:69.261	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting	ICD10CM	2019	2.16.840.1.113883.6.90	PT
229:69.262	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting	ICD10CM	2019	2.16.840.1.113883.6.90	PT
230:69.263	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting	ICD10CM	2019	2.16.840.1.113883.6.90	PT
231:69.264	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting	ICD10CM	2019	2.16.840.1.113883.6.90	PT
232:69.265	Other paralytic syndrome following other nontraumatic intracranial hemorrhage, bilateral	ICD10CM	2019	2.16.840.1.113883.6.90	PT
233:69.269	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting	ICD10CM	2019	2.16.840.1.113883.6.90	PT
234:69.290	Apraxia following other nontraumatic intracranial hemorrhage	ICD10CM	2019	2.16.840.1.113883.6.90	PT
235:69.291	Dysphagia following other nontraumatic intracranial hemorrhage	ICD10CM	2019	2.16.840.1.113883.6.90	PT
236:69.292	Facial weakness following other nontraumatic intracranial hemorrhage	ICD10CM	2019	2.16.840.1.113883.6.90	PT
237:69.293	Ataxia following other nontraumatic intracranial hemorrhage	ICD10CM	2019	2.16.840.1.113883.6.90	PT
238:69.298	Other sequelae of other nontraumatic intracranial hemorrhage	ICD10CM	2019	2.16.840.1.113883.6.90	PT
239:69.30	Unspecified sequelae of cerebral infarction	ICD10CM	2019	2.16.840.1.113883.6.90	PT
240:69.310	Attention and concentration deficit following cerebral infarction	ICD10CM	2019	2.16.840.1.113883.6.90	PT
241:69.311	Memory deficit following cerebral infarction	ICD10CM	2019	2.16.840.1.113883.6.90	PT
242:69.312	Visuospatial deficit and spatial neglect following cerebral infarction	ICD10CM	2019	2.16.840.1.113883.6.90	PT
243:69.313	Psychomotor deficit following cerebral infarction	ICD10CM	2019	2.16.840.1.113883.6.90	PT
244:69.314	Frontal lobe and executive function deficit following cerebral infarction	ICD10CM	2019	2.16.840.1.113883.6.90	PT
245:69.315	Cognitive social or emotional deficit following cerebral infarction	ICD10CM	2019	2.16.840.1.113883.6.90	PT
246:69.318	Other symptoms and signs involving cognitive functions following cerebral infarction	ICD10CM	2019	2.16.840.1.113883.6.90	PT

Value Set Info Expansion List

Mapping to Local Data

Variable name	Variable description	Data type	Date specification	Centricity table	Centricity column	Centricity value	HDID for OBS	Data value	Questions/com
PatientID		Numeric		PatientProfile	PatientID				
HealthCenterID				PatientProfile	HealthCenterID				
Race	6 Main Categories								
Ethnicity	Hispanic/Latino, Not HHispanic/Latino								
Sex	Male, Female, Unknown								
Insurance Status	Insured, Uninsured, Patient's Primary Insurance							Selfpay OR Unknown = Uninsured. Else insured	
Age			as of 1/31/2019						
Age Category	Ages 21-24		as of 1/31/2019						
	Ages 25-34								
	Ages 35-44								
	Ages 45-54								
	Ages 55-64								
	Ages 65-74								
Language	Best Served in a Language Other Than English. UDS Definition	Y/N							
LDL Name	Recorded as the highest fasting or direct laboratory test result in the measurement year or during the two years prior to the beginning of the measurement period		Highest value between 2/1/2016-1/31/2019	Obs	ObsName	LDL	30		
						LDL DIR	21893		
						LDL (CALCUL)	3891		
						LDL	30		

Building Logic

The screenshot displays the PopulationBuilder interface. On the left, a sidebar lists filter categories: Organization Center, Patient, Diagnosis, Encounter, Lab Result, Medication Order, and Medication Administration. The main workspace shows a sequence of filters connected by AND operators:

- Organization Center Filter (Organization ID: ACIL)
- Patient Filter (Age: 21 years and older)
- Encounter Filter (Encounter Type: Adult Office Visit, COVIDOFFICE, and 24 others; Start Date: Within the last year)
- Diagnosis Filter (Code: I10 Atherosclerosis and Peripheral Arterial Disease)
- Medication Order Filter (Medication Description: #ATORVASTATIN 10 MG TABLET, #ATORVASTATIN 20 MG TABLET, and 1111 others)

A 'Generated SQL' window is open, showing the following query:

```
COMPONENTS: ALRESORGANIZATIONID, ALRESLENTERID
*/
IF OBJECT_ID('tempdb..#rule_0_0_ACRESorganizationCenter') IS NOT NULL
DROP TABLE #rule_0_0_ACRESorganizationCenter
GO
SELECT query.* INTO #rule_0_0_ACRESorganizationCenter
FROM (
    SELECT source.EDWPatientID AS EDWPatientID
    FROM SharedLocal.Person.Patient AS source
    INNER JOIN SharedLocal.Security.PatientOrgCenterLinkage AS c1 ON
    source.EDWPatientID = c1.EDWPatientID
    WHERE c1.OrganizationID IN ('ACIL') AND c1.RowSourceDesc IN
    ('Centricity.ACIL.UF','Centricity.ACIL.WH','Centricity.ACIL.AL','Centricity.ACIL.EF
    ','Centricity.ACIL.PN','Centricity.ACIL.PH','Centricity.ACIL.FP','Centricity.ACIL.H
    HC','Centricity.ACIL.HP','Centricity.ACIL.HM','Centricity.ACIL.HI','Centricity.ACIL
    HC','Centricity.ACIL.HB','Centricity.ACIL.IM','Centricity.ACIL.IC','Centricity.ACIL
    LC','Centricity.ACIL.MA','Centricity.ACIL.IN','Centricity.ACIL.NC','Centricity.ACIL
    L.SH','Centricity.ACIL.SA','Centricity.ACIL.TC','Centricity.ACIL.TP','Centricity.AC
    IL.WM','Centricity.ACIL.TS','Centricity.ACIL.WY','Centricity.ACIL.MK','Centricity.A
    CIL.NS')
    GROUP BY source.EDWPatientID
) AS query;
```

Measuring Testing/Validation

PID	ETHNICITY	Sex	Age	AgeCategory	ASCVDCode	ASCVDOnsetDate	LDLEver	LDL3YR	LDLMostRecent	Statin	DiabetesCode	DiabetesOr	Hyperchole	Hypercholesterolem	RiskGroup1_NUM	RiskGroup1	RiskG
635956517966	Not Hispanic	F	28	Ages 25-34	G45.8	1/5/2015 0:00	86		86						N	Y	N
735050337882	Hispanic or M		40	Ages 35-44	G45.9	2/21/2017 0:00	179	179	179	ATORVASTATIN CALCIUM 40 MG ORAL TABLET					Y	Y	N
738215666104	Hispanic or F		62	Ages 55-64	G45.9	9/11/2014 0:00	119	110	110	ATORVASTATIN CALCIUM 40 MG ORAL TABLET					Y	Y	N
742580478318	Not Hispanic	M	63	Ages 55-64	G45.9	9/12/2019 0:00	186	186	186	LIPITOR 20 MG ORAL TABLET					Y	Y	N
743742622252	Unspecifie	F	46	Ages 45-54	G45.9	5/15/2019 0:00				LIPITOR 40 MG ORAL TABLET	E11.9	#####			Y	Y	N
628927487384	Not Hispanic	F	37	Ages 35-44	G45.9	6/28/2019 0:00	114	103	103	ATORVASTATIN CALCIUM 20 MG ORAL TABLET					Y	Y	N
629122868976	Not Hispanic	F	57	Ages 55-64	G45.9	10/15/2014 0:00	116	87	87	ATORVASTATIN CALCIUM 40 MG ORAL TABLET					Y	Y	N
207690004732	Not Hispanic	F	46	Ages 45-54	G45.9	9/11/2015 0:00	175	165	165	ATORVASTATIN CALCIUM 40 MG ORAL TABLET					Y	Y	N
732998831166	Not Hispanic	F	46	Ages 45-54	G45.9	8/26/2019 0:00	144	69	69	ATORVASTATIN CALCIUM 40 MG ORAL TABLET					Y	Y	N
733020586718	Not Hispanic	F	46	Ages 45-54	G45.9	3/22/2016 0:00	216	186	186	SIMVASTATIN 40 MG TABLET					Y	Y	Y
735893888492	Not Hispanic	F	51	Ages 45-54	G45.9	3/6/2016 0:00	58	58	58						N	Y	N
736117510464	Not Hispanic	F	66	Ages 65-74	G45.9	1/31/2013 0:00	149	149	149	ATORVASTATIN CALCIUM 20MG TABLET					Y	Y	N
736827912912	Not Hispanic	F	46	Ages 45-54	G45.9	5/27/2015 0:00	128	110	110	ATORVASTATIN CALCIUM 20 MG ORAL TABLET					Y	Y	N
738964872926	Not Hispanic	M	50	Ages 45-54	G45.9	8/24/2017 0:00	120	120	120						N	Y	N
737930542860	Not Hispanic	F	57	Ages 55-64	G45.9	2/23/2017 0:00	137	137	137	SIMVASTATIN 40 MG ORAL TABLET	E11.9	#####			Y	Y	N
738119962594	Not Hispanic	M	51	Ages 45-54	G45.9	3/1/2018 0:00	177	69	69	ATORVASTATIN CALCIUM 80 MG ORAL TABLET					Y	Y	N
738265574442	Not Hispanic	M	65	Ages 65-74	G45.9	3/27/2019 0:00	65	62	62	LIPITOR 10 MG ORAL TABLET					Y	Y	N
740088317080	Not Hispanic	M	49	Ages 45-54	G45.9	6/26/2019 0:00	152	102	102	LOVASTATIN 20 MG ORAL TABLET					Y	Y	N
741515606804	Not Hispanic	F	52	Ages 45-54	G45.9	8/31/2017 0:00	90	80	80	ATORVASTATIN CALCIUM 10 MG ORAL TABLET	E11.9	#####			Y	Y	N
741756277598	Not Hispanic	F	59	Ages 55-64	G45.9	7/24/2018 0:00	122	122	122	ATORVASTATIN 40MG TABLETS	E11.9	#####			Y	Y	N
742342422374	Not Hispanic	M	51	Ages 45-54	G45.9	10/26/2018 0:00	118	115	115	ATORVASTATIN CALCIUM 10 MG ORAL TABLET					Y	Y	N
743026885510	Not Hispanic	M	55	Ages 55-64	G45.9	10/15/2018 0:00	108	78	78	ATORVASTATIN CALCIUM 40 MG ORAL TABLET	E11.65	#####			Y	Y	N
740869111290	Not Hispanic	F	55	Ages 55-64	G45.9	2/9/2018 0:00	143	124	124	ATORVASTATIN CALCIUM 20 MG ORAL TABLET					Y	Y	N
741110932618	Not Hispanic	F	52	Ages 45-54	G45.9	8/29/2019 0:00	109		109	ATORVASTATIN CALCIUM 80 MG ORAL TABLET					Y	Y	N

Chart Review- Denominator

- Data element | **Diagnosis: Cerebrovascular disease, Stroke, TIA**

Value Set Description from VSAC

CLINICAL FOCUS: This value set contains concepts that represent stroke and high risk diagnoses associated with stroke, including transient ischemic attack (TIA) and generalized ischemic cerebrovascular disease, which would indicate a patient has atherosclerotic cardiovascular disease (ASCVD) in relation to a cerebrovascular event.


DATA ELEMENT SCOPE: This value set may use the Quality Data Model (QDM) category or attribute related to Diagnosis.

INCLUSION CRITERIA: Includes only relevant concepts associated with ASCVD diagnoses of cerebrovascular origin.

EXCLUSION CRITERIA: No exclusions.

Constrained to codes in the Diagnosis: Cerebrovascular disease, Stroke, TIA value set [\(2.16.840.1.113762.1.4.1047.44\)](#)

Problems				
Description	ICD-9	ICD-10	Onset Date	End
Transient ischemic attack	435.9	G45.9	03-Jan-2020	
Stroke	434.91	I63.9	10-Mar-2020	



Name: Cerebrovascular disease, Stroke, TIA
Code System: ICD10CM, ICD9CM, SNOMEDCT
OID: 2.16.840.1.113762.1.4.1047.44
Steward: [Contact](#) Quality Insights of Pennsylvania



Chart Review- Numerator

- Data element | Medication, Order: Low intensity statin therapy

Value Set Description from VSAC

CLINICAL FOCUS: This value set contains concepts that represent low intensity statin medications as defined by the 2013 American College of Cardiology (ACC) and the American Heart Association (AHA) guideline.

DATA ELEMENT SCOPE: This value set may use the Quality Data Model (QDM) category related to Medication.

INCLUSION CRITERIA: Includes only relevant concepts associated with low intensity statin therapy medications.

EXCLUSION CRITERIA: Excludes any other intensity of statin therapy.

Constrained to codes in the Medication, Order: Low intensity statin therapy value set ([2.16.840.1.113762.1.4.1047.107](#))

The screenshot shows a 'Medications' interface with a search bar and a list of medications. The search bar contains 'Alliance Statins'. The list includes:

Description	Instructions	Route	Last Rx	Generic	Start Date
SIMVASTATIN 10 MG...	Take one daily	ORAL		SIMVASTATIN	06-Jan-2020
OXYCODONE HCL 20...		ORAL		OXYCODONE...	17-Jul-2020

Below the main list, a scrollable area shows a detailed list of medications with their prices:

PRAVASTATIN SODIUM 20 MG ORAL TABLET	Take one daily 30	\$3.27
PRAVASTATIN SODIUM 40 MG ORAL TABLET	Take one daily 30	\$4.79
PRAVASTATIN SODIUM 80 MG ORAL TABLET	Take one daily 30	\$4.79
SIMVASTATIN 10 MG ORAL TABLET	Take one daily 30	\$2.82
SIMVASTATIN 20 MG ORAL TABLET	Take one daily 30	\$4.92
SIMVASTATIN 40 MG ORAL TABLET	Take one daily 30	\$4.92

Aggregate Report

		Month of Measurement																		
		Jan-19	Feb-19	Mar-19	Apr-19	May-19	Jun-19	Jul-19	Aug-19	Sep-19	Oct-19	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20	May-20	Jun-20	Jul-20
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	Statin Therapy - All Risk Groups																			
	Number of patients in denominator who received a prescription for statin therapy on or after 6/1/2019	5554	5578	5575	5709	5916	6085	6201	6247	6355	6415	6402	6436	6511	6658	6715	6640	6504	6451	0
	Number of patients ages 21+ years with 1+ visits in the past 12 months who met the above risk group criteria	11366	11439	11472	11553	11688	11763	11863	11956	12156	12333	12401	12604	12798	12915	13005	12967	12807	12751	0
		48.9%	48.8%	48.6%	49.4%	50.6%	51.7%	52.3%	52.2%	52.3%	52.0%	51.6%	51.1%	50.9%	51.6%	51.6%	51.2%	50.8%	50.6%	#DIV/0!
	Statin Therapy - Diagnosis of ASCVD																			
	Number of patients in denominator who are actively using or who receive an order (prescription) for statin therapy at any point during the measurement period	231	239	250	263	268	275	282	281	280	291	298	324	348	353	356	357	355	366	
	Number of patients ages 21+ years with 1+ visits in the past 12 months who met the following risk group criteria: Adults age 21+ years with a diagnosis of ASCVD*	299	309	315	326	328	338	340	341	343	359	363	366	375	383	389	388	385	394	
		77.3%	77.3%	79.4%	80.7%	81.7%	81.4%	82.9%	82.4%	81.6%	81.1%	82.1%	88.5%	92.8%	92.2%	91.5%	92.0%	92.2%	92.9%	#DIV/0!
	Statin Therapy - LDL \geq 190 mg/DL																			
	Number of patients in denominator who are actively																			

Program and Roll-Out

- Clinical committee buy-in
- Training on workflow
- Consideration of unintended consequences
- Wraparound support

Statin on Medication List: Ensure the patient's statin medication is on the Medication List. Refer to the Disease Management Advisor for clinical decision support on statin prescribing, and the Alliance Statins Medication Custom List for easy access to prescribing recommended statins.

EHR Location: AC Clinical Content - Form
Name: Disease Management Advisor
Folder Path: Enterprise/Alliance/Disease Management

The screenshot displays the 'Disease Management Advisor' interface. At the top, it shows 'ANA/ACC ASCVD Risk Estimator' and 'Framingham Risk Calculator'. The patient's chronic conditions are listed as 'Asthma, HIV, Obesity, Depression'. The 'Problems' section includes 'MODERATE OBESITY', 'LIVER DISEASE', 'DEPRESSION', 'SMOKING', 'LACK OF VEGETABLE FOOD', 'MIGRAINE HEADACHE', and 'TOOTH EXTRACTION'. The 'Medications' section lists various drugs including 'SEREVENT DISKUS', 'BUDERSON', 'PULMICORT FLEXHALER', 'BRIQOR-ACTIVATED', 'PURISSENDE', and 'COMBIVR'. Below this, risk scores are shown: ANA/ACC ASCVD Risk Estimator (29.7%), Framingham Risk Calculator (14%), and ANA/ACC CVD Risk Estimator (7.6%). The recommendation is 'Mod/High Intensity Statin'. A 'Statin Info' window is open, showing a list of statin medications with columns for 'Statin', 'Directions', 'Quantity', 'Refills', and 'Add Statin'. An orange callout box at the bottom of the screenshot contains the text: 'Easy access to the Alliance Statins Medication Custom List, to start the statin prescription from this form.' An arrow points from this callout to the 'Add Statin' button in the 'Statin Info' window.

Engage and Get Help

- eCQI Resource Center and Contact Email
 - <https://ecqi.healthit.gov>
 - ecqi-resource-center@hhs.gov
- Share feedback on the Measure Collaboration Workspace
 - <https://ecqi.healthit.gov/contact>
- Explore the CMS Measures Inventory Tool
 - <https://cmit.cms.gov/cmit/#/>
- Engage with the eCQI community
 - <https://ecqi.healthit.gov/engage-ecqi>
- Learn about eCQM communication resources
 - <https://ecqi.healthit.gov/sites/default/files/eCQMCommunicationResources.pdf>

Additional Resources and Contact Information

- ONC Project Issue Tracking System (Jira)
 - <https://oncprojecttracking.healthit.gov>
- eCQI Community Engagement Opportunities
 - <https://ecqi.healthit.gov/engage-ecqi>